Basilea Pharmaceutica - Public Comps and Valuation Multiples

Basilea Pharmaceutica Overview

About Basilea Pharmaceutica

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Founded

2000

HQ

Employees

189

Website

basilea.com

Sectors

Drug Development & Therapeutics
Biopharmaceuticals
BioTech

Financials

LTM Revenue $294M

LTM EBITDA $68.1M

EV

$870M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Basilea Pharmaceutica Financials

As of January 2026, Basilea Pharmaceutica reported last 12-month revenue of $294M and EBITDA of $68.1M.

In the same period, Basilea Pharmaceutica generated $245M in LTM gross profit and $51.6M in net income.

See Basilea Pharmaceutica valuation multiples based on analyst estimates

Basilea Pharmaceutica P&L

In the most recent fiscal year, Basilea Pharmaceutica reported revenue of $272M and EBITDA of $86.5M.

Basilea Pharmaceutica expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Basilea Pharmaceutica valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$294M	XXX	$272M	XXX	XXX	XXX
Gross Profit	$245M	XXX	$221M	XXX	XXX	XXX
Gross Margin	83%	XXX	81%	XXX	XXX	XXX
EBITDA	$68.1M	XXX	$86.5M	XXX	XXX	XXX
EBITDA Margin	23%	XXX	32%	XXX	XXX	XXX
EBIT	$65.3M	XXX	$79.7M	XXX	XXX	XXX
EBIT Margin	22%	XXX	29%	XXX	XXX	XXX
Net Profit	$51.6M	XXX	$101M	XXX	XXX	XXX
Net Margin	18%	XXX	37%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Basilea Pharmaceutica including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $294M. EBITDA for the last twelve months was $68.1M. In the most recent fiscal year, Basilea Pharmaceutica achieved $272M in revenue and $86.5M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$294M	Analyst estimates available to subscribers	$272M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$245M	Analyst estimates available to subscribers	$221M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	83.3% gross margin	Analyst estimates available to subscribers	81.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$68.1M	Analyst estimates available to subscribers	$86.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	23.1% EBITDA margin	Analyst estimates available to subscribers	31.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$65.3M	Analyst estimates available to subscribers	$79.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	22.2% EBIT margin	Analyst estimates available to subscribers	29.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$51.6M	Analyst estimates available to subscribers	$101M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	17.5% net profit margin	Analyst estimates available to subscribers	37.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Basilea Pharmaceutica

This financial data table provides comprehensive performance metrics for Basilea Pharmaceutica, a company based in Switzerland. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Basilea Pharmaceutica generated $294M in revenue over the last twelve months.
The company achieved $68.1M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $245M.
Net income over the last twelve months reached $51.6M.

Fiscal Year Performance

In the most recent fiscal year, Basilea Pharmaceutica reported $272M in total revenue.
Fiscal year EBITDA was $86.5M.
The company maintained a gross profit margin of 81.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 31.8%.
Net profit margin reached 37.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Basilea Pharmaceutica. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Basilea Pharmaceutica Stock Performance

Basilea Pharmaceutica has current market cap of CHF 699M (or $912M), and EV of CHF 668M (or $870M).

Market Cap Evolution

Basilea Pharmaceutica Stock Data

As of February 24, 2026, Basilea Pharmaceutica's stock price is CHF 57 (or $74).

See Basilea Pharmaceutica trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$870M	$912M	XXX	XXX	XXX	XXX	$4.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Basilea Pharmaceutica Valuation Multiples

Basilea Pharmaceutica's trades at 3.0x EV/Revenue multiple, and 12.8x EV/EBITDA.

See valuation multiples for Basilea Pharmaceutica and 15K+ public comps

Basilea Pharmaceutica Financial Valuation Multiples

As of February 24, 2026, Basilea Pharmaceutica has market cap of $912M and EV of $870M.

Equity research analysts estimate Basilea Pharmaceutica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Basilea Pharmaceutica has a P/E ratio of 17.7x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$912M	XXX	$912M	XXX	XXX	XXX
EV (current)	$870M	XXX	$870M	XXX	XXX	XXX
EV/Revenue	3.0x	XXX	3.0x	XXX	XXX	XXX
EV/EBITDA	12.8x	XXX	12.8x	XXX	XXX	XXX
EV/EBIT	13.3x	XXX	13.3x	XXX	XXX	XXX
EV/Gross Profit	3.6x	XXX	n/a	XXX	XXX	XXX
P/E	17.7x	XXX	17.7x	XXX	XXX	XXX
EV/FCF	12.3x	XXX	12.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Basilea Pharmaceutica Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Basilea Pharmaceutica Margins & Growth Rates

Basilea Pharmaceutica's last 12 month revenue growth is 12%

Basilea Pharmaceutica's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $0.7M for the same period.

Basilea Pharmaceutica's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Basilea Pharmaceutica's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Basilea Pharmaceutica and other 15K+ public comps

Basilea Pharmaceutica Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	12%	XXX	5%	XXX	XXX	XXX
EBITDA Margin	23%	XXX	23%	XXX	XXX	XXX
EBITDA Growth	31%	XXX	50%	XXX	XXX	XXX
Rule of 40	26%	XXX	35%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	52%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.7M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	37%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	52%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial